Pancreatic Cancer Research

ResearcherNational Physical LaboratoryActive in the last 2 years

Agnieszka Lemańska

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4849-2430; OpenAlex author ID A5087145085. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
13
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 12

  1. Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis. Last author DOI 10.1002/cam4.71997↗
  2. Comparing Weight Loss Prior to Pancreatic Cancer Diagnosis in Cases and Controls: A Systematic Review and Meta-Analysis. Last author DOI 10.3233/shti260172↗
  3. Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC): external validation using English sentinel network. Last author DOI 10.3399/bjgp.2024.0253↗
  4. Pancreatic Cancer Risk Assessment Tools in Primary Care: A Mixed Methods Systematic Review. Last author DOI 10.1007/s12029-025-01229-5↗
  5. Sociodemographic Profile of People with Diagnosed Pancreatic Cancer in the UK: Retrospective Sentinel Network Cohort Study. Last author DOI 10.3233/shti250563↗
  6. Using Data to Improve Healthcare: A Case Study of Pancreatic Enzyme Replacement in Pancreatic Cancer. Last author DOI 10.1016/j.soncn.2024.151688↗
  7. External UK validation of the ENDPAC model to predict pancreatic cancer risk: A registered report protocol Last author DOI 10.1101/2024.05.21.24307690↗
  8. Determining the feasibility of calculating pancreatic cancer risk scores for people with new-onset diabetes in primary care (DEFEND PRIME): study protocol. Last author DOI 10.1136/bmjopen-2023-079863↗
  9. A National Audit of Pancreatic Enzyme Prescribing in Pancreatic Cancer from 2015 to 2023 in England Using OpenSAFELY-TPP. Co-author DOI 10.1016/j.soncn.2023.151439↗
  10. Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: A cohort study using OpenSAFELY-TPP. Co-author DOI 10.7554/elife.85332↗
  11. BMI and HbA1c are metabolic markers for pancreatic cancer: Matched case-control study using a UK primary care database. Co-author DOI 10.1371/journal.pone.0275369↗
  12. Using Primary Care Data to Report Real-World Pancreatic Cancer Survival and Symptomatology. Co-author DOI 10.3233/shti210142↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Claire A. Price · 7 shared papers, 2022–2026 · strength 1.89
  2. Simon de Lusignan · 7 shared papers, 2021–2026 · strength 1.65
  3. Hugh Claridge · 4 shared papers, 2024–2026 · strength 1.06
  4. Natalia I. Khalaf · 3 shared papers, 2024–2026 · strength 0.73
  5. Brian MacKenna · 3 shared papers, 2023–2024 · strength 0.53
  6. Ben M. Goldacre · 3 shared papers, 2023–2024 · strength 0.53
  7. Keith John Roberts · 3 shared papers, 2023–2024 · strength 0.53
  8. Alex J. Walker · 3 shared papers, 2023–2024 · strength 0.53
  9. Nathan Jeffreys · 2 shared papers, 2021–2022 · strength 0.25
  10. T Varghese · 1 shared paper, 2024 · strength 0.20
  11. Asma Sultana · 1 shared paper, 2024 · strength 0.20
  12. Rupaly Pandé · 1 shared paper, 2024 · strength 0.20
  13. Adam Enver Frampton · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.